Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Frieda Kontsioti"'
Autor:
Anthi Bouchla, Georgia Delikonstantinou, Theodoros Loupis, Frieda Kontsioti, Vasiliki Bakou, Maria Dellatola, Eleftheria Hatzimichael, Maria Pagoni, Elisavet Apostolidou, Konstantinos Theodorakopoulos, Papageorgiou Sotirios, Vasiliki Pappa
Publikováno v:
HemaSphere, Vol 7, p e2717259 (2023)
Externí odkaz:
https://doaj.org/article/18e76910add441c9809d397c866bc6ff
Autor:
Vassiliki Mpakou, Evangelia Papadavid, Frieda Kontsioti, Eugene Konsta, Miriam Vikentiou, Aris Spathis, Sotiris Papageorgiou, Diamantina Vasilatou, Konstantinos Gkontopoulos, Efthimia Mpazani, Petros Karakitsos, Dimitrios Rigopoulos, George Dimitriadis, Vasiliki Pappa
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170186 (2017)
Mycosis fungoides (MF) and its leukemic variant Sézary syndrome (SS) comprise the majority of CTCL, a heterogenous group of non-Hodgkins lymphomas involving the skin. The CTCL's resistance to chemotherapy and the lack of full understanding of their
Externí odkaz:
https://doaj.org/article/bbc757a1367948719e4542f16c086675
Autor:
Serena Valsami, Vassiliki Pappa, Dimitra Rontogianni, Frieda Kontsioti, Efstathios Papageorgiou, John Dervenoulas, Themis Karmiris, Sotirios Papageorgiou, Nikolaos Harhalakis, Nikolaos Xiros, Emmanuel Nikiforakis, Theofanis Economopoulos
Publikováno v:
Haematologica, Vol 92, Iss 10 (2007)
Background and Objectives Although most patients with classical Hodgkin’s lymphoma (CHL) are cured, a significant minority are refractory to treatment. The investigation of biological markers could improve the predictive capacity of clinical stagin
Externí odkaz:
https://doaj.org/article/8ab191eb96464b5c981d86e345173f4c
Autor:
Anthi Bouchla, Theodoros Loupis, Georgia Delikonstantinos, Frieda Kontsioti, Vassiliki Mpakou, Maria Dellatola, Maria Pagoni, Konstantinos Theodorakopoulos, Sotirios Papageorgiou, Argiris Symeonidis, Vassiliki Pappa
Publikováno v:
Blood. 140:6250-6251
Autor:
Vassiliki Mpakou, Aris Spathis, Anthi Bouchla, Zoi Tsakiraki, Frieda Kontsioti, Sotirios Papageorgiou, Efthymia Bazani, Konstantinos Gkontopoulos, Thomas Thomopoulos, Irene Glezou, Athanasios Galanopoulos, Argiris Symeonidis, Panagiotis T. Diamantopoulos, Nora‐Athina Viniou, Christina‐Nefeli Kontandreopoulou, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, Eleftheria Lamprianidou, Periklis Foukas, Aristoteles Mpamias, Vasiliki Pappa
Publikováno v:
Hematological Oncology. 39
Autor:
null Vassiliki Mpakou, null Aris Spathis, null Anthi Bouchla, null Zoi Tsakiraki, null Frieda Kontsioti, null Sotirios Papageorgiou, null Efthymia Bazani, null Konstantinos Gkontopoulos, null Thomas Thomopoulos, null Irene Glezou, null Athanasios Galanopoulos, null Argiris Symeonidis, null Panagiotis T. Diamantopoulos, null Nora‐Athina Viniou, null Christina‐Nefeli Kontandreopoulou, null Kalliopi Zafeiropoulou, null Ioannis Kotsianidis, null Eleftheria Lamprianidou, null Periklis Foukas, null Aristoteles Mpamias, null Vasiliki Pappa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::736b52559d7fc080a714c89d7f3f4675
https://doi.org/10.1002/hon.2834/v2/response1
https://doi.org/10.1002/hon.2834/v2/response1
Autor:
Irene Glezou, Nora-Athina Viniou, Eleftheria Lamprianidou, Periklis G. Foukas, Konstantinos Gkontopoulos, Panagiotis T. Diamantopoulos, Efthymia Bazani, Frieda Kontsioti, Thomas P. Thomopoulos, Christina-Nefeli Kontandreopoulou, Vassiliki E. Mpakou, Vasiliki Pappa, Ioannis Kotsianidis, Zoi Tsakiraki, Sotirios G. Papageorgiou, Aristoteles Mpamias, Argiris Symeonidis, Anthi Bouchla, Athanasios Galanopoulos, Aris Spathis, Kalliopi Zafeiropoulou
Publikováno v:
Hematological oncologyREFERENCES. 39(2)
5-azacytidine (5-AZA) is considered the standard of care for patients with high-risk myelodysplastic syndromes (MDS) and patients with acute myeloid leukemia (AML) not candidate for intensive chemotherapy. However, even after an initial favorable res
Autor:
Vassiliki Pappa, Zoi Tsakiraki, Aris Spathis, Frieda Kontsioti, Athanasios Galanopoulos, Periklis G. Foukas, Vassiliki E. Mpakou, Efthimia Mpazani, Nora-Athina Viniou, Argiris Symeonidis, Ioannis Kotsianidis, Anthi Bouhla, Kalliopi Zafeiropoulou, Georgia Stavroulaki, Sotirios G. Papageorgiou, Irene Glezou, Konstantinos Gkodopoulos
Publikováno v:
Blood. 134:5403-5403
Introduction: Azacitidine (AZA) is a hypomethylating agent that at low doses acts by inhibiting DNA methyltranferase activity. AZA is approved and widely used for the treatment of MDS patients and patients with AML not candidate for intensive chemoth
Autor:
Georgia Stavroulaki, Anthi Bouhla, Vassiliki E. Mpakou, Argiris Symeonidis, Thomas P. Thomopoulos, Vassiliki Pappa, George Dimitriadis, Frieda Kontsioti, Sotirios G. Papageorgiou, Konstantinos Gkodopoulos, Eirini Glezou, Efthimia Bazani, Eirini Maratou
Publikováno v:
Blood. 134:5176-5176
INTRODUCTION AML is the most common malignant myeloid disorder in adults. Relapses are initiated by chemoresistant leukemic cells. DNA damage and repair mechanisms influence not only the genetic predisposition to leukemia but are also very important
Autor:
Efthymia Bazani, Irene Glezou, Diamantina Vasilatou, E. Maratou, T. Thomopoulos, G. Dimitriadis, A. Bouhla, Vassiliki Pappa, Frieda Kontsioti, Georgia Stavroulaki, Vassiliki E. Mpakou, S. Papageorgiou
Publikováno v:
HemaSphere. 3:784-785